What is the share price of Astal Laboratories Ltd (ASTALLTD) today?
The share price of ASTALLTD as on 13th November 2026 is ₹63.24. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Astal Laboratories Ltd (ASTALLTD) share?
The past returns of Astal Laboratories Ltd (ASTALLTD) share are- Past 1 week: 4.77%
- Past 1 month: -4.18%
- Past 3 months: -28.53%
- Past 6 months: -21.87%
- Past 1 year: -33.27%
- Past 3 years: 78.57%
- Past 5 years: 696.59%
What are the peers or stocks similar to Astal Laboratories Ltd (ASTALLTD)?
The peers or stocks similar to Astal Laboratories Ltd (ASTALLTD) include:What is the market cap of Astal Laboratories Ltd (ASTALLTD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astal Laboratories Ltd (ASTALLTD) is ₹276.33 Cr as of 13th November 2026.What is the 52 week high and low of Astal Laboratories Ltd (ASTALLTD) share?
The 52-week high of Astal Laboratories Ltd (ASTALLTD) is ₹98.74 and the 52-week low is ₹49.99.What is the PE and PB ratio of Astal Laboratories Ltd (ASTALLTD) stock?
The P/E (price-to-earnings) ratio of Astal Laboratories Ltd (ASTALLTD) is 18.79. The P/B (price-to-book) ratio is 0.83.Which sector does Astal Laboratories Ltd (ASTALLTD) belong to?
Astal Laboratories Ltd (ASTALLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Astal Laboratories Ltd (ASTALLTD) shares?
You can directly buy Astal Laboratories Ltd (ASTALLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Astal Laboratories Ltd
ASTALLTD Share Price
BSEASTALLTD Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ASTALLTD Performance & Key Metrics
ASTALLTD Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 9.45 | 0.83 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.36 | 6.07 | 0.47% |
ASTALLTD Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
ASTALLTD Company Profile
Astal Laboratories Ltd is engaged in the pharmaceutical bulk drug business, owning a manufacturing plant for pharmaceutical intermediates in Karnataka.
ASTALLTD Forecast
ASTALLTD Forecasts
ASTALLTD
ASTALLTD
Income
Balance Sheet
Cash Flow
ASTALLTD Income Statement
ASTALLTD Income Statement
| Quarter | mar 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | sep 2026 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 23.50 | 37.55 | 52.27 | 134.15 | 101.07 | 108.20 | ||||||
| Operating & Other expenses | 19.28 | 33.65 | 48.68 | 123.86 | 88.69 | 90.65 | ||||||
| EBITDA | 4.22 | 3.90 | 3.59 | 10.29 | 12.38 | 17.55 | ||||||
| Depreciation/Amortization | 0.10 | 0.12 | 0.12 | 0.86 | 0.86 | 0.88 | ||||||
| PBIT | 4.12 | 3.78 | 3.47 | 9.43 | 11.52 | 16.67 | ||||||
| Interest & Other Items | 0.27 | 0.31 | 0.33 | 1.09 | 1.18 | 1.34 | ||||||
| PBT | 3.85 | 3.47 | 3.14 | 8.34 | 10.34 | 15.33 | ||||||
| Taxes & Other Items | 1.10 | 0.88 | 0.77 | 0.66 | 0.93 | 5.56 | ||||||
| Net Income | 2.75 | 2.59 | 2.37 | 7.68 | 9.41 | 9.77 | ||||||
| EPS | 2.80 | 2.40 | 2.19 | 2.04 | 2.19 | 2.23 |
ASTALLTD Company Updates
ASTALLTD Stock Peers
ASTALLTD Past Performance & Peer Comparison
ASTALLTD Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Astal Laboratories Ltd | 18.79 | 0.83 | — |
| Sun Pharmaceutical Industries Limited | 36.15 | 5.38 | 0.85% |
| Torrent Pharmaceuticals Ltd | 80.71 | 10.10 | 0.72% |
| Laurus Labs Ltd | 147.36 | 24.11 | 0.08% |
ASTALLTD Stock Price Comparison
Compare ASTALLTD with any stock or ETFASTALLTD Holdings
ASTALLTD Shareholdings
ASTALLTD Promoter Holdings Trend
ASTALLTD Promoter Holdings Trend
ASTALLTD Institutional Holdings Trend
ASTALLTD Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding History
ASTALLTD Shareholding History
smallcases containing ASTALLTD stock
smallcases containing ASTALLTD stock
Looks like this stock is not in any smallcase yet.
ASTALLTD Events
ASTALLTD Events
ASTALLTD Dividend Trend
ASTALLTD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
ASTALLTD Dividend Trend
ASTALLTD has not given any dividends in last 5 years
ASTALLTD Dividends
ASTALLTD Dividends
ASTALLTD Stock News & Opinions
ASTALLTD Stock News & Opinions
Astal Laboratories Ltd's net profit grew slightly 3.72% to Rs 9.77 crore, while revenue from operations slightly gained 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, easing 6.94%. It has improved by 2.52% over last one week and ticked higher by 5.98% in last one month while the market capitalization of Astal Laboratories Ltd has marginally improved by 4.47% and 26.80% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, expanding by 341.79% year-on-year, and surging by 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, rallying 343.49% YoY and jumping 40.63% sequentially. Total expenses posted a minor rise of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tumbling by 12.38% YoY. For FY26, revenue from operations jumped by 287.87% to Rs 249.13 crore, while net profit jumped 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA surged by 1265% to Rs 20.55 crore, and PBT surged 48% to Rs 17.73 crore compared to previous FY. The company's consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd tumbled by 33.27% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.42% during the same period.
Astal Laboratories Ltd's net profit grew slightly 3.72% to Rs 9.77 crore, while revenue from operations improved marginally 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.94%. It has improved by 2.52% over last one week and moved up slightly by 5.98% in last one month while the market capitalization of Astal Laboratories Ltd has inched up 4.47% and 26.80% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, surging by 341.79% year-on-year, and rallying 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, expanding by 343.49% YoY and jumping 40.63% sequentially. Total expenses saw a slight increase of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tanking by 12.38% YoY. For FY26, revenue from operations witnessed a strong growth of 287.87% to Rs 249.13 crore, while net profit surged by 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA soared by 1265% to Rs 20.55 crore, and PBT witnessed a strong rise of 48% to Rs 17.73 crore compared to previous FY. The company's consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd plunged by 33.27% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.
Astal Laboratories Limited will hold a meeting of its Board of Directors on November 13, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a Limited Review Report from the auditors. The company has closed the trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the board meeting's conclusion, in accordance with SEBI regulations.
Astal Laboratories Limited submitted a certificate to the BSE Limited on October 14, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2026. The certificate, received from BEETAL FINANCIAL & COMPUTER SERVICES (P) LTD., the company's Registrar and Share Transfer Agent, verifies that securities received for dematerialization were confirmed to the depositories and that security certificates have been mutilated and cancelled.
Astal Laboratories Limited informed the BSE Limited that the trading window for dealing in securities of the company will be closed for all directors, officers, designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.
Astal Laboratories Limited will hold a meeting of its Board of Directors on September 4, 2026, at its corporate office in Telangana to consider and approve the notice for the company’s 33rd Annual General Meeting, approve the Board Report for the financial year ended March 31, 2026, and appoint a scrutinizer for the AGM and remote e-voting.
Astal Laboratories Limited will hold a meeting of its Board of Directors on August 14, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a Limited Review Report from the auditors.
Net profit of Astal Laboratories rose 180.29% to Rs 7.68 crore in the quarter ended March 2026 as against Rs 2.74 crore during the previous quarter ended March 2025. Sales rose 471.15% to Rs 134.05 crore in the quarter ended March 2026 as against Rs 23.47 crore during the previous quarter ended March 2025. For the full year,net profit rose 64.73% to Rs 14.71 crore in the year ended March 2026 as against Rs 8.93 crore during the previous year ended March 2025. Sales rose 287.87% to Rs 249.13 crore in the year ended March 2026 as against Rs 64.23 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.0523.47 471 249.1364.23 288 OPM %7.6017.81 -8.3419.88 - PBDT9.203.95 133 18.9612.20 55 PBT8.343.85 117 17.7311.98 48 NP7.682.74 180 14.718.93 65 Powered by Capital Market - Live
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 30 May 2026.
Net profit of Astal Laboratories declined 5.22% to Rs 2.36 crore in the quarter ended December 2025 as against Rs 2.49 crore during the previous quarter ended December 2024. Sales rose 261.27% to Rs 52.24 crore in the quarter ended December 2025 as against Rs 14.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales52.2414.46 261 OPM %6.7822.96 - PBDT3.253.10 5 PBT3.133.02 4 NP2.362.49 -5 Powered by Capital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant